Andrew Lassman

Chief, Neuro-Oncology Division

Columbia University Irving Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2025

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2025

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2025

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.

Year:

2025

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.

Year:

2024

Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.

Year:

2024

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2024

Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50

Year:

2024

Collaborators (31)

Joseph G. Jurcic

Columbia University Irving Medical Center

UNITED STATES
View details

Prabhjot Mundi

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Peter Sims

Assistant Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Riccardo Soffietti

-

ITALY
View details

Hanina Hibshoosh

Professor of pathology at CUIMC

Columbia University

UNITED STATES
View details

Guy M. McKhann

Florence Irving Associate Professor of Neurological Surgery

Columbia University Irving Medical Center

UNITED STATES
View details

Tobias Walbert

-

UNITED STATES
View details

Ana Tergas

Rutgers, The State Univ. of NJ

UNITED STATES
View details

Kenneth Olive

Assistant Dean of Graduate Curricula and Associate Professor of Medicine

Columbia University Irving Medical Center

UNITED STATES
View details

Guarionex Joel DeCastro

Associate Professor

Columbia University

UNITED STATES
View details

Jason D. Wright

-

UNITED STATES
View details

Andrew Kung

Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mariano Alvarez

Chief Scientific Officer

KweHealth, LLC

UNITED STATES
View details

Gary K. Schwartz

Case Western Reserve University

UNITED STATES
View details

Dawn L. Hershman

Columbia University Irving Medical Center

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Katherine Crew

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Alfred I. Neugut

-

UNITED STATES
View details

Daniel Diolaiti

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Michael Kluger

Professor of Surgery

NYU Langone Health

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Roy E. Strowd

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Eugene Douglass

Assistant Professor

University of Georgia

UNITED STATES
View details

Howard Colman

Professor

-

UNITED STATES
View details

Peter Hau

University of Regensburg

GERMANY
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Priya Kumthekar

Northwestern Medicine

UNITED STATES
View details

Louis Nabors

Professor

The University of Alabama

UNITED STATES
View details

Melissa K. Accordino

Columbia University

UNITED STATES
View details

Annick Desjardins

Professor of Neurosurgery and Neurology

Duke University

UNITED STATES
View details

Jeffrey Bruce

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center

UNITED STATES
View details